{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:28:49Z","timestamp":1784410129797,"version":"3.55.0"},"reference-count":21,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage kidney disease (ESKD) in patients with type 2 diabetes, but uncertainty about the balance between risks and benefits exists. Here, we examine the long-term effects of intensive glucose control on risk of ESKD and other outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Survivors, previously randomized to intensive or standard glucose control, were invited to participate in post-trial follow-up. ESKD, defined as the need for dialysis or kidney transplantation, or death due to kidney disease, was documented overall and by baseline CKD stage, along with hypoglycemic episodes, major cardiovascular events, and death from other causes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 8,494 ADVANCE participants were followed for a median of 5.4 additional years. In-trial HbA1c differences disappeared by the first post-trial visit. The in-trial reductions in the risk of ESKD (7 vs. 20 events, hazard ratio [HR] 0.35, P = 0.02) persisted after 9.9 years of overall follow-up (29 vs. 53 events, HR 0.54, P &amp;lt; 0.01). These effects were greater in earlier-stage CKD (P = 0.04) and at lower baseline systolic blood pressure levels (P = 0.01). The effects of glucose lowering on the risks of death, cardiovascular death, or major cardiovascular events did not differ by levels of kidney function (P &amp;gt; 0.26).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Intensive glucose control was associated with a long-term reduction in ESKD, without evidence of any increased risk of cardiovascular events or death. These benefits were greater with preserved kidney function and with well-controlled blood pressure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc15-2322","type":"journal-article","created":{"date-parts":[[2016,3,23]],"date-time":"2016-03-23T03:50:29Z","timestamp":1458705029000},"page":"694-700","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":211,"title":["Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON"],"prefix":"10.2337","volume":"39","clinical-trial-number":[{"clinical-trial-number":"nct00949286","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Muh Geot","family":"Wong","sequence":"first","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chalmers","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"},{"name":"The George Institute for Global Health, University of Oxford, Oxford, U.K."},{"name":"Department of Epidemiology, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Baker IDI Heart and Diabetes Institute, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Hamet","sequence":"additional","affiliation":[{"name":"Centre hospitalier de l`Universite de Montreal, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harrap","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heller","sequence":"additional","affiliation":[{"name":"University of Sheffield and Sheffield Teaching Hospitals, National Health Service Foundation Trust, Sheffield, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"MacMahon","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"},{"name":"The George Institute for Global Health, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[{"name":"Policlinico di Monza and IRCCS Istituto Auxologico Italiano, University of Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[{"name":"H\u00f4pital Bichat-Claude Bernard and Universit\u00e9 Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Matthews","sequence":"additional","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"},{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Poulter","sequence":"additional","affiliation":[{"name":"International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, University College, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zoungas","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of Sydney, Sydney, Australia"},{"name":"School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"2022031221172116000_B1"},{"key":"2022031221172116000_B2","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: a systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"2022031221172116000_B3"},{"key":"2022031221172116000_B4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrneph.2009.76","article-title":"Emerging therapies for chronic kidney disease: what is their role","volume":"5","author":"Vilayur","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"2022031221172116000_B7","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B8","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"2022031221172116000_B11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"key":"2022031221172116000_B12","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"2022031221172116000_B14","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B15"},{"key":"2022031221172116000_B16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00125-014-3369-7","article-title":"Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes","volume":"57","author":"Zoungas","year":"2014","journal-title":"Diabetologia"},{"key":"2022031221172116000_B17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"2022031221172116000_B19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199807093390202","article-title":"Reversal of lesions of diabetic nephropathy after pancreas transplantation","volume":"339","author":"Fioretto","year":"1998","journal-title":"N Engl J Med"},{"key":"2022031221172116000_B20","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/0140-6736(93)92183-T","article-title":"Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys","volume":"342","author":"Fioretto","year":"1993","journal-title":"Lancet"},{"key":"2022031221172116000_B21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00041552-200007000-00001","article-title":"Cellular and molecular mediators in common pathway mechanisms of chronic renal disease progression","volume":"9","author":"Taal","year":"2000","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/5\/694\/626153\/dc152322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/5\/694\/626153\/dc152322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:27:08Z","timestamp":1647127628000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/5\/694\/30742\/Long-term-Benefits-of-Intensive-Glucose-Control"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,3,22]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-2322","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,22]]}}}